Safety of Breztri Inhaler in Patients with Thyroid Cancer
Yes, it is safe to continue Breztri inhaler in patients with newly diagnosed thyroid cancer, as there are no contraindications or warnings related to thyroid cancer in the FDA drug label.
Key Safety Considerations
After reviewing the FDA drug label for Breztri (budesonide/glycopyrrolate/formoterol) and related triple therapy inhalers containing fluticasone furoate/umeclidinium/vilanterol, there are no documented contraindications, warnings, or precautions specifically related to thyroid cancer or any malignancy 1, 2.
What the Evidence Shows
The FDA drug labels for these triple therapy inhalers detail extensive safety warnings including:
- Asthma-related deaths with LABA monotherapy
- Deterioration of disease and acute episodes
- Oropharyngeal candidiasis
- Pneumonia risk in COPD patients
- Immunosuppression
- Adrenal suppression
- Cardiovascular effects
- Urinary retention
- Ocular effects (glaucoma, cataracts)
Notably absent from this comprehensive list is any mention of cancer as a contraindication or safety concern 1, 2.
Real-World Safety Data
Recent post-marketing surveillance from Japan (2026) involving 286 patients with asthma treated with fluticasone furoate/umeclidinium/vilanterol demonstrated:
- Overall adverse drug reaction rate of 8.4%
- Most common reactions were cough and dysphonia
- Low incidence of cardiovascular events
- No new safety concerns identified 3
Clinical Recommendation
Continue the Breztri inhaler without interruption. The patient's COPD or asthma management should not be compromised by the thyroid cancer diagnosis, as:
- There is no pharmacological interaction between inhaled corticosteroids/LABAs/LAMAs and thyroid cancer
- Discontinuing effective respiratory therapy could lead to exacerbations, which would negatively impact the patient's overall health status during cancer treatment
- The systemic absorption of inhaled medications is minimal compared to oral corticosteroids
Important Monitoring Points
While continuing Breztri is safe, monitor for:
- Immunosuppression effects: Patients on inhaled corticosteroids have some degree of immunosuppression, though far less than systemic steroids. This is relevant if the patient requires surgery or other cancer treatments 1
- Adrenal function: If the patient needs systemic corticosteroids for any reason during cancer treatment, be aware of potential adrenal suppression from chronic ICS use 1
- Standard COPD/asthma monitoring parameters remain unchanged
The thyroid cancer diagnosis does not alter the risk-benefit profile of continuing Breztri for respiratory disease management.